Lecture Notes

**Lecture Coverage:**
- Basic Principles of Current Anticancer Drug Therapies
- Traditional Chemotherapy Drugs
- Precision Drugs against Cancer Hallmarks

---
#### **Basic Principles of Current Anticancer Drug Therapies**
**Selective Toxicity**
- Maximal Harm to Cancer Cells & Minimal Harm to Normal Cells
	- Goal: Destroy all Malignant cells to prevent recurrence
	- Ideal scenario: A drug kills cancer cells specifically
- Requires understanding differences between cancer & normal cells

**Current Status**
- First Order Kinetics
	- Constant Fraction of cancer cells are killed with each dose → Multiple rounds of therapy needed

**Current Challenges**

|        Challenge        | Description                                                                                                                         |
| :---------------------: | ----------------------------------------------------------------------------------------------------------------------------------- |
|     Low Selectivity     | Rapidly Dividing Cells as Target<br>→ Harm <abbr Title="Bone Marrow, Hair Follicle & Gut Lining">normal fast-growing tissues</abbr> |
|     Drug Resistance     | Primary / Acquired Resistance                                                                                                       |
| Inter-patient Variation | Varied tumors →<br>Need for Personalized Chemotherapy                                                                               |


#### **Traditional Chemotherapy Drugs**

|              Type              |                                Drug Examples                                 | Mechanism of Action                                                                                       |
| :----------------------------: | :--------------------------------------------------------------------------: | --------------------------------------------------------------------------------------------------------- |
|     <br>Alkylating Agents      | Cis<font color=yellow>platin</font><br>Carbo<font color=yellow>platin</font> | Covalent Alkylation & Cross-Link Formation in DNA<br>→ No DNA Replication & Transcription<br>→ Cell Death |
|    <br><br>Antimetabolites     |                   <abbr Title="5-Fluorouracil">5-FU</abbr>                   | Thymidylate Synthase Inhibitor<br>→ ↓ Thymine for Nucleotide Synthesis                                    |
|               ^                |                                 Methotrexate                                 | Dihydrofolate Reductase Inhibitor<br>→ ↓ Folate for Nucleotide Synthesis                                  |
|          Antibiotics           |                                  Bleomycin                                   | Free Radical Generation → DNA Strand Break                                                                |
|    Topoisomerase Inhibitors    |                         Anthracyclines<br>Etoposide                          | No regulation on DNA supercoiling & tangles<br>→ DNA Strand Break                                         |
| <br><br>Microtubule Inhibitors |                        Vinca Alkaloids (Vincristine)                         | ↓ Microtubule Polymerization in Mitosis<br>→ Mitosis Arrest                                               |
|               ^                |                             Taxanes (Paclitaxel)                             | ↓ Microtubule Depolymerization in Mitosis<br>→ Mitosis Arrest                                             |
|      <br>Hormone Therapy       |                          Anti-Estrogens (Tamoxifen)                          | <br>Hormone Receptor Antagonists / Inhibitors in Synthesis<br>→ Suppress Cancer Growth                    |
|               ^                |                          Anti-Androgens (Flutamide)                          | ^                                                                                                         |
|               ^                |                            Anti-LHRH (Degarelix)                             | ^                                                                                                         |


#### **Precision Drugs against Cancer Hallmarks**
|              Hallmark Targeted              |                                   Drug Type                                   |                                 Drug Examples                                  | Mechanism of Action                                                                                                                   |
| :-----------------------------------------: | :---------------------------------------------------------------------------: | :----------------------------------------------------------------------------: | ------------------------------------------------------------------------------------------------------------------------------------- |
| <br><br><br><br><br>Proliferative Signaling |                      <br><br>Tyrosine Kinase Inhibitors                       |                       Ima<font color=yellow>tinib</font>                       | Bcr-Abl Inhibitor in <abbr Title="Chronic Myeloid Leukemia">CML</abbr><br>→ ↓ Abnormally Activated Tyrosine Kinase for Proliferation  |
|                      ^                      |                                       ^                                       |                Gefi<font color=yellow>tinib</font><br>(Iressa)                 | EFGR Inhibitor in <abbr Title="Non-Small Cell Lung Cancer">NSCLC</abbr><br>→ ↓ Abnormally Activated Tyrosine Kinase for Proliferation |
|                      ^                      |                              <br><br>Antibodies                               |                      Cetuxi<font color=yellow>mab</font>                       | EFGR Inhibitor<br>→ ↓ Abnormal Activated Tyrosine Kinase for Proliferation                                                            |
|                      ^                      |                                       ^                                       |                     Trastuzu<font color=yellow>mab</font>                      | HER2 Inhibitor<br>→ ↓ Abnormal Activated Tyrosine Kinase for Proliferation                                                            |
|                 Cell Cycle                  |        <abbr Title="Cyclin-Dependent Cyclase">CDK</abbr>4/6 Inhibitors        | Palbo<font color=yellow>ciclib</font><br>Ribo<font color=yellow>ciclib</font>  | ↓ G1 Phase Progression → Cell Cycle Arrest                                                                                            |
|             Genome Instability              |                                PARP Inhibitors                                |                       Ola<font color=yellow>parib</font>                       | PARP Inhibition → ↓ Single-Strand Break Repair<br>→ Synthetic Lethality in BRCA cancerous cells without homologous recombination      |
|                Immune Escape                |                         Immune Checkpoint Inhibitors                          | Pembrolizu<font color=yellow>mab</font><br>Nivolu<font color=yellow>mab</font> | PD-1/PD-L1 Inhibition → ↓ Inhibitory Signal on T-cells<br>→ ↑ Cancer Cell Recognition & Elimination                                   |
|                Angiogenesis                 | <abbr Title="Vascular Endothelial Growth Factor">VEGF</abbr>/VEGFR Inhibitors |                            Bevacizumab<br>Sunitinib                            | VEGF/VEGFR Inhibition<br>→ ↓ Blood Vessel Formation for Tumor Growth & Metastasis                                                     |

